365 related articles for article (PubMed ID: 24306059)
1. Protective mechanisms of adenosine 5'-monophosphate in platelet activation and thrombus formation.
Fuentes E; Badimon L; Caballero J; Padró T; Vilahur G; Alarcón M; Pérez P; Palomo I
Thromb Haemost; 2014 Mar; 111(3):491-507. PubMed ID: 24306059
[TBL] [Abstract][Full Text] [Related]
2. Chlorogenic acid inhibits human platelet activation and thrombus formation.
Fuentes E; Caballero J; Alarcón M; Rojas A; Palomo I
PLoS One; 2014; 9(3):e90699. PubMed ID: 24598787
[TBL] [Abstract][Full Text] [Related]
3. Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation.
Münzer P; Borst O; Walker B; Schmid E; Feijge MA; Cosemans JM; Chatterjee M; Schmidt EM; Schmidt S; Towhid ST; Leibrock C; Elvers M; Schaller M; Seizer P; Ferlinz K; May AE; Gulbins E; Heemskerk JW; Gawaz M; Lang F
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):61-71. PubMed ID: 24233488
[TBL] [Abstract][Full Text] [Related]
4. Strawberry extract presents antiplatelet activity by inhibition of inflammatory mediator of atherosclerosis (sP-selectin, sCD40L, RANTES, and IL-1β) and thrombus formation.
Alarcón M; Fuentes E; Olate N; Navarrete S; Carrasco G; Palomo I
Platelets; 2015; 26(3):224-9. PubMed ID: 24749953
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet activation and thrombus formation by adenosine and inosine: studies on their relative contribution and molecular modeling.
Fuentes E; Pereira J; Mezzano D; Alarcón M; Caballero J; Palomo I
PLoS One; 2014; 9(11):e112741. PubMed ID: 25393959
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A
Fuentes E; Fuentes M; Caballero J; Palomo I; Hinz S; El-Tayeb A; Müller CE
Platelets; 2018 May; 29(3):292-300. PubMed ID: 28504052
[TBL] [Abstract][Full Text] [Related]
7. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
Zhao L; Bath PM; May J; Lösche W; Heptinstall S
Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J; Klinkhardt U; Harder S
Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
[TBL] [Abstract][Full Text] [Related]
9. Effect of the hydrogen sulfide donor GYY4137 on platelet activation and microvascular thrombus formation in mice.
Grambow E; Mueller-Graf F; Delyagina E; Frank M; Kuhla A; Vollmar B
Platelets; 2014; 25(3):166-74. PubMed ID: 23586391
[TBL] [Abstract][Full Text] [Related]
10. Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.
Schneider DJ; Sobel BE
Coron Artery Dis; 2009 Mar; 20(2):175-8. PubMed ID: 19194284
[TBL] [Abstract][Full Text] [Related]
11. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
13. Platelets enhance lymphocyte adhesion and infiltration into arterial thrombus.
Hu H; Zhu L; Huang Z; Ji Q; Chatterjee M; Zhang W; Li N
Thromb Haemost; 2010 Dec; 104(6):1184-92. PubMed ID: 20838746
[TBL] [Abstract][Full Text] [Related]
14. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
15. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ
Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836
[TBL] [Abstract][Full Text] [Related]
16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
17. ADAM 15 is an adhesion receptor for platelet GPIIb-IIIa and induces platelet activation.
Langer H; May AE; Bültmann A; Gawaz M
Thromb Haemost; 2005 Sep; 94(3):555-61. PubMed ID: 16268472
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of caffeic acid on ADP-induced thrombus formation and platelet activation involves mitogen-activated protein kinases.
Lu Y; Li Q; Liu YY; Sun K; Fan JY; Wang CS; Han JY
Sci Rep; 2015 Sep; 5():13824. PubMed ID: 26345207
[TBL] [Abstract][Full Text] [Related]
20. A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity.
Han X; Knauss EA; Fuente M; Li W; Conlon RA; LePage DF; Jiang W; Renna SA; McKenzie SE; Nieman MT
J Thromb Haemost; 2024 Jun; 22(6):1715-1726. PubMed ID: 38508397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
